Oramed Pharmaceuticals Introduces New Rights Agreement
Oramed Pharmaceuticals Inc. has made an important announcement regarding a new Rights Agreement, aimed at ensuring fair treatment for its shareholders. The Board of Directors has unanimously adopted this innovative Rights Plan, which aligns with the goal of protecting shareholder interests in potential takeover situations.
Details of the Rights Distribution
The company has declared a significant dividend distribution, offering one common stock purchase right (referred to as a "Right") for every outstanding share of its common stock, which has a par value of $0.012 per share. The introduction of the Rights is a proactive measure to uphold equitable conditions during any hostile takeover attempt. This strategy allows the Board of Directors a stronger position to negotiate with potential acquiring entities, safeguarding the interests of all stockholders.
Initial Rights Entitlements
Initially, each Right grants stockholders the ability to purchase one additional share of Common Stock at a predetermined price of $10.00, should the Rights become exercisable. The plan stipulates that the Rights will become exercisable ten business days following a person or group acquiring 15% or more of the outstanding shares or announcing a tender offer for a similar percentage. Furthermore, the Board retains the authority to redeem these Rights at $0.012 each before a triggering event occurs.
Events Leading to Exercisability
Consequently, if the ownership threshold needed to trigger the Rights Plan is reached, each Right allows its holder to buy shares of Common Stock—or receive equivalent cash or assets—valued at twice the exercise price. It is crucial to note that any Rights held by the triggering person will be rendered void, emphasizing the plan's protective features. The Board may also opt to exchange the exercisable Rights for shares of Common Stock, further enhancing shareholder value.
Important Dates and Considerations
The dividend distribution is set to occur on a specified date for stockholders on record, solidifying transparency within the shareholder community. The Rights will expire three years from the adoption of the Rights Plan unless they are redeemed or exchanged sooner by the company. This initiative is designed with the shareholders' best interests in mind, and notably, the Rights distribution is not taxable for stockholders.
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) is a frontrunner in oral drug delivery systems, focused on transforming the landscape of biopharmaceutical administration. Known for its cutting-edge Protein Oral Delivery (POD™) technology, the company is pioneering methods that protect the integrity of drugs while significantly improving absorption rates. Oramed's vision includes providing patients with a more convenient means of medication administration, moving away from traditional injections.
Frequently Asked Questions
What is the Rights Agreement announced by Oramed?
The Rights Agreement is a protective measure implemented to ensure fair treatment for shareholders in the event of a hostile takeover.
What are stock purchase rights?
Stock purchase rights allow shareholders to buy additional shares at a specified price, which helps maintain their ownership percentage in case of potential takeover attempts.
When will the Rights distribution take effect?
The Rights distribution will take effect on a specified date for shareholders on record, allowing them to participate in the Rights Plan.
How does the exercisability of Rights work?
The Rights will become exercisable after certain ownership thresholds are reached, enabling stockholders to purchase common stock at a predetermined price.
Is the Rights distribution taxable?
No, the Rights distribution is not taxable for shareholders, providing a clear benefit to stockholders.
